OBJECTIVE: High circulating concentrations of parathyroid hormone (PTH) have been associated with increased risks of hypertension, left ventricular hypertrophy, congestive heart failure and cardiovascular mortality. Impaired arterial function is a potential mechanism for these associations. We tested whether serum PTH concentration is associated with measures of arterial function. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 6545 persons without clinical cardiovascular disease participating in the community-based Multi-Ethnic Study of Atherosclerosis. MEASUREMENTS: Brachial artery flow-mediated dilation (FMD) as well as aortic pulse pressure and arterial pulse parameters derived from Windkessel modelling of the radial pressure waveform. RESULTS: Higher serum PTH concentration was associated with lower brachial artery FMD (mean difference -0·09% per 10 pg/ml PTH), higher aortic pulse pressure (0·53 mmHg per 10 pg/ml) and reduced Windkessel capacitive index C1 (large artery elasticity, -0·12 ml/mmHg × 10 per 10 pg/ml), adjusting for potential confounding variables (all P-values ≤ 0·001). These relationships were independent of serum calcium concentration, serum 25-hydroxyvitamin D concentration and estimated glomerular filtration rate and were consistent across relevant participant subgroups. Associations of PTH with aortic pulse pressure and capacitive index C1 were attenuated after adjustment for blood pressure. Serum PTH concentration was not associated with the oscillatory index C2 (small artery elasticity). CONCLUSIONS: Higher serum PTH concentration was associated with impaired endothelial function, increased aortic pulse pressure and decreased capacitive index C1 in a large, diverse, community-based population. These relationships may help explain previously observed associations of elevated PTH with cardiovascular disease.
OBJECTIVE: High circulating concentrations of parathyroid hormone (PTH) have been associated with increased risks of hypertension, left ventricular hypertrophy, congestive heart failure and cardiovascular mortality. Impaired arterial function is a potential mechanism for these associations. We tested whether serum PTH concentration is associated with measures of arterial function. DESIGN: Cross-sectional study. PARTICIPANTS: A total of 6545 persons without clinical cardiovascular disease participating in the community-based Multi-Ethnic Study of Atherosclerosis. MEASUREMENTS: Brachial artery flow-mediated dilation (FMD) as well as aortic pulse pressure and arterial pulse parameters derived from Windkessel modelling of the radial pressure waveform. RESULTS: Higher serum PTH concentration was associated with lower brachial artery FMD (mean difference -0·09% per 10 pg/ml PTH), higher aortic pulse pressure (0·53 mmHg per 10 pg/ml) and reduced Windkessel capacitive index C1 (large artery elasticity, -0·12 ml/mmHg × 10 per 10 pg/ml), adjusting for potential confounding variables (all P-values ≤ 0·001). These relationships were independent of serum calcium concentration, serum 25-hydroxyvitamin D concentration and estimated glomerular filtration rate and were consistent across relevant participant subgroups. Associations of PTH with aortic pulse pressure and capacitive index C1 were attenuated after adjustment for blood pressure. Serum PTH concentration was not associated with the oscillatory index C2 (small artery elasticity). CONCLUSIONS: Higher serum PTH concentration was associated with impaired endothelial function, increased aortic pulse pressure and decreased capacitive index C1 in a large, diverse, community-based population. These relationships may help explain previously observed associations of elevated PTH with cardiovascular disease.
Authors: A Piovesan; N Molineri; F Casasso; I Emmolo; G Ugliengo; F Cesario; G Borretta Journal: Clin Endocrinol (Oxf) Date: 1999-03 Impact factor: 3.478
Authors: T Stefenelli; C Abela; H Frank; J Koller-Strametz; S Globits; J Bergler-Klein; B Niederle Journal: J Clin Endocrinol Metab Date: 1997-01 Impact factor: 5.958
Authors: P N Sambrook; J S Chen; L M March; I D Cameron; R G Cumming; S R Lord; J Schwarz; M J Seibel Journal: J Clin Endocrinol Metab Date: 2004-11 Impact factor: 5.958
Authors: Cassianne Robinson-Cohen; Michael Shlipak; Mark Sarnak; Ronit Katz; Carmen Peralta; Bessie Young; Andrew N Hoofnagle; Moyses Szklo; Joachim H Ix; Bruce M Psaty; Ian H de Boer; Bryan Kestenbaum; Nisha Bansal Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Pamela L Lutsey; Mary R Rooney; Aaron R Folsom; Erin D Michos; Alvaro Alonso; Weihong Tang Journal: Vasc Med Date: 2018-02-05 Impact factor: 3.239
Authors: Cassianne Robinson-Cohen; Leila R Zelnick; Andrew N Hoofnagle; Pamela L Lutsey; Gregory Burke; Erin D Michos; Steven J C Shea; Russell Tracy; David S Siscovick; Bruce Psaty; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Adriana J van Ballegooijen; Cassianne Robinson-Cohen; Ronit Katz; Michael Criqui; Matthew Budoff; Dong Li; David Siscovick; Andy Hoofnagle; Steven J Shea; Gregory Burke; Ian H de Boer; Bryan Kestenbaum Journal: Bone Date: 2015-05-11 Impact factor: 4.398
Authors: Nicholas O Palmeri; Karina W Davidson; William Whang; Ian M Kronish; Donald Edmondson; Marcella D Walker Journal: Ann Noninvasive Electrocardiol Date: 2017-09-26 Impact factor: 1.468
Authors: Megan A Evans; Hyun Ah Kim; T Michael De Silva; Thiruma V Arumugam; Andrew N Clarkson; Grant R Drummond; Graeme R Zosky; Brad Rs Broughton; Christopher G Sobey Journal: J Cereb Blood Flow Metab Date: 2017-08-23 Impact factor: 6.200
Authors: Jessica B Kendrick; Leila Zelnick; Michel B Chonchol; David Siscovick; Andrew N Hoofnagle; Joachim H Ix; Mark Sarnak; Michael G Shlipak; Bryan Kestenbaum; Ian H de Boer Journal: Am J Nephrol Date: 2016-12-10 Impact factor: 3.754
Authors: Aaron R Folsom; Alvaro Alonso; Jeffrey R Misialek; Erin D Michos; Elizabeth Selvin; John H Eckfeldt; Josef Coresh; James S Pankow; Pamela L Lutsey Journal: Am Heart J Date: 2014-06-09 Impact factor: 4.749